secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2025-07-01T23:59:59+00:00
Accession:  0001193125-25-154016
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inmagene doses first patient in Phase 2b ADAPTIVE trial of IMG-007 for atopic dermatitis; data expected Q4 2026
--------------------------------------------------------------------------------

- IMG-007 targets OX40 receptor with silenced ADCC to minimize safety risks and extended half-life for convenient dosing.
- ADAPTIVE trial is a global Phase 2b enrolling ~220 patients across three IMG-007 dose arms and placebo.
- Primary endpoint: mean percentage change from baseline in EASI score at Week 20.
- Topline results from the Phase 2b trial are expected in the fourth quarter of 2026.
- Dose-finding study designed to guide optimal dosing for future Phase 3 trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312525154016/0001193125-25-154016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312525154016/d917926d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-154016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer